TOP TEN perturbations for 39317_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39317_at
Selected probe(set): 205518_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39317_at (205518_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):6.8303647Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):6.7653537Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
CH5183284 study 1 (HSC-39) / vehicle (DMSO) treated HSC-39 cell sample
Relative Expression (log2-ratio):4.986601Number of Samples:2 / 2
| Experimental | CH5183284 study 1 (HSC-39) |
| Human gastric cell line HSC-39 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HSC-39 cell sample |
| Human gastric cell line HSC-39 treated with 0.1% DMSO for 24 hours. |
wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)
Relative Expression (log2-ratio):-4.716857Number of Samples:3 / 3
| Experimental | wound healing study 2 (ex vivo; AG1478) |
| Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:--- | |
| Control | normal skin tissue (ex vivo) |
| Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. |
wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)
Relative Expression (log2-ratio):-4.3973856Number of Samples:3 / 3
| Experimental | wound healing study 2 (ex vivo; DMSO) |
| Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. | |
| Control | normal skin tissue (ex vivo) |
| Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. |
precursor-B-ALL study 3 (E2A-PBX1) / T-ALL study 3
Relative Expression (log2-ratio):-4.371997Number of Samples:6 / 29
| Experimental | precursor-B-ALL study 3 (E2A-PBX1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | T-ALL study 3 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
basal cell carcinoma study 3 / normal epidermal keratinocytes
Relative Expression (log2-ratio):4.2685785Number of Samples:4 / 2
| Experimental | basal cell carcinoma study 3 |
| Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC). | |
| Control | normal epidermal keratinocytes |
| Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2. |
VTX-2337 study 1 / 3M-055 study 1
Relative Expression (log2-ratio):4.162073Number of Samples:3 / 3
| Experimental | VTX-2337 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
| Control | 3M-055 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist. |
precursor-B-ALL study 3 (hyperdiploid) / T-ALL study 3
Relative Expression (log2-ratio):-4.1489344Number of Samples:17 / 29
| Experimental | precursor-B-ALL study 3 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | T-ALL study 3 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
VTX-2337 study 1 / untreated monocyte sample
Relative Expression (log2-ratio):3.9761467Number of Samples:3 / 3
| Experimental | VTX-2337 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
| Control | untreated monocyte sample |
| Peripheral blood monocytes isolated from healthy donors. |